STOCK TITAN

Vivos Therapeutics Inc - VVOS STOCK NEWS

Welcome to our dedicated news page for Vivos Therapeutics (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vivos Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vivos Therapeutics's position in the market.

Rhea-AI Summary
Vivos Therapeutics, Inc. announces the immediate exercise of a common stock purchase warrant by an institutional investor, resulting in gross proceeds of approximately $4.0 million. The investor will purchase 980,393 shares of Vivos common stock at a revised exercise price of $4.02 per share. In return, Vivos will issue two new unregistered warrants to the investor, each allowing the purchase of 735,296 shares at an exercise price of $5.05 per share. The transaction is expected to close by February 20, 2024, with net proceeds intended for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.14%
Tags
none
-
Rhea-AI Summary
Vivos Therapeutics, Inc. (VVOS) highlights favorable market developments, including United Healthcare's updated medical policy and recent recalls of CPAP devices by ResMed and Philips Respironics, creating significant revenue opportunities for the company's oral appliance therapies. The FDA granted a 510(k) clearance to Vivos CARE appliances to treat moderate and severe OSA in adults. Vivos is well-positioned to assist patients and providers affected by the discontinuation of CPAP devices by Philips Respironics, offering a safe and effective alternative treatment option. United Healthcare's revised OSA medical treatment policy further supports the use of oral appliance therapy, providing a substantial opportunity for Vivos to expand its user base.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
none
-
Rhea-AI Summary
Vivos Therapeutics, Inc. (NASDAQ:VVOS) announced a significant increase in new dentist inquiries, VIP enrollment contracts, and CARE oral medical device orders following the FDA clearance of its oral medical devices to treat severe obstructive sleep apnea (OSA). The company reported a 600% rise in new dentist inquiries, 38% sequential increase in signed VIP enrollment contracts, and a 26% increase in CARE appliance orders. Vivos expects these positive metrics to drive revenue growth in 2024, with a 53% increase in sales of pediatric guided growth and development appliances. Toothpillow, a key dental service organization partner, also experienced a surge in interest and new patient inquiries, indicating a growing market for Vivos products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
clinical trial
Rhea-AI Summary
Vivos Therapeutics, Inc. (VVOS) has received FDA 510(k) clearance for its oral device to treat severe OSA, leading to the 'Empowering Women to Champion Airway' event to unite influential women in medicine and dentistry. The event aims to foster collaboration and empower women to drive positive transformations in healthcare. Vivos' CARE appliances have been granted FDA clearance to treat moderate and severe OSA in adults, providing a new alternative to CPAP or surgery. The company is hosting a conference to enhance collaboration between medical and dental professionals to provide optimal treatment solutions for patients with sleep and breathing disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.44%
Tags
none
-
Rhea-AI Summary
Vivos Therapeutics, Inc. (NASDAQ: VVOS) has received FDA clearance for treating severe obstructive sleep apnea (OSA) in adults using the Vivos' removable CARE oral appliances, marking the first time the FDA has approved an oral appliance to treat moderate and severe OSA in adults. The statistically significant data submitted to the FDA from 73 severe OSA patients showed that 80% of patients experienced an improvement of at least 1 classification or at least a 50% improvement in the Apnea Hypopnea Index (AHI), and 97% of patients improved or stayed the same, with an average treatment time of just 9.7 months. The company believes this unprecedented decision by the FDA will generate broader acceptance throughout the medical community for Vivos treatment options, leading to the potential for higher patient referrals and case starts as well as collaboration with medical professionals, enhancing their value proposition to third-party distribution partners such as durable medical equipment (DME) companies, and clearing the way for greater reimbursement levels from medical insurance payors and Medicare, favorably impacting their ability to grow revenues in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
833.94%
Tags
clinical trial
-
Rhea-AI Summary
Vivos Therapeutics, Inc. (NASDAQ: VVOS) reported a 32% year-over-year decrease in operating expenses and a 19% sequential decrease. New strategic relationships, including a U.S. nationwide distribution agreement with Lincare, are expected to bring significant new revenue opportunities. The company's cost-cutting measures have led to a 61% reduction in net loss for the third quarter of 2023, and a 47% reduction for the nine months ended September 30, 2023. Vivos also completed a private placement for net proceeds of approximately $3.5 million in November 2023 to augment its liquidity position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.22%
Tags
earnings
Rhea-AI Summary
Vivos Therapeutics, Inc. (NASDAQ: VVOS) plans to release its third quarter 2023 financial results after market close on November 14, 2023. The company will conduct a conference call at 5:00 p.m. (Eastern Time) the same day to review the results and provide an overview of recent milestones and developments. Investors can access the conference call via phone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.84%
Tags
earnings
-
Rhea-AI Summary
Vivos Therapeutics, Inc. has closed a $4 million private placement, with net proceeds of approximately $3.5 million. The company plans to use the funds for general working capital. In the private placement, Vivos issued 980,393 shares of common stock at a purchase price of $4.08 per share. They also issued a Series A Warrant and a Series B Warrant to purchase additional shares. A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.52%
Tags
none
-
Rhea-AI Summary
Vivos Therapeutics, Inc. has entered into a securities purchase agreement with an institutional investor for the purchase and sale of 980,393 shares of its common stock at a price of $4.08 per share. Additionally, the investor will receive a five-year Series A Warrant and an eighteen-month Series B Warrant to purchase additional shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.19%
Tags
none
Rhea-AI Summary
Vivos Therapeutics, Inc. will undergo a 1-for-25 reverse stock split of its common stock, effective October 27, 2023. The reverse stock split aims to bring Vivos into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market. The number of outstanding shares will be reduced from 29,928,786 shares to approximately 1,197,151 shares. Shareholders with fractional shares will have them rounded up to the nearest whole share. The exercise prices of outstanding options and warrants will be adjusted accordingly. Vivos' transfer agent, VStock Transfer LLC, will handle the exchange process for stockholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2229.14%
Tags
none
Vivos Therapeutics Inc

Nasdaq:VVOS

VVOS Rankings

VVOS Stock Data

7.31M
817.72k
15.22%
19.21%
2.19%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Littleton

About VVOS

vivos therapeutics, inc., a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (sdb) comprising mild-to-moderate obstructive sleep apnea (osa). the company's solutions cover proprietary alternatives for treating mild-to-moderate osa; craniofacial and anatomical anomalies that are associated with mild-to-moderate osa. its treatment for osa involves specially designed and customized oral appliances and treatment protocols. the company, through its vivos integrated healthcare network, provides access to healthcare providers for delivering care for patients suffering from sleep disordered breathing, including mild-to-moderate osa. vivos therapeutics, inc. also licenses its intellectual property to third-party manufacturers, which fabricate appliance devices for healthcare professionals. it caters to general dentists, medical doctors, myofunctional therapists, chiropractors, healthcare providers,